These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 8420132)

  • 1. Are dopaminergic neurons selectively vulnerable to Parkinson's disease?
    Agid Y; Ruberg M; Javoy-Agid F; Hirsch E; Raisman-Vozari R; Vyas S; Faucheux B; Michel P; Kastner A; Blanchard V
    Adv Neurol; 1993; 60():148-64. PubMed ID: 8420132
    [No Abstract]   [Full Text] [Related]  

  • 2. [Mechanism of cell death in neurodegenerative disorders: apropos of Parkinson disease].
    Agid Y
    C R Seances Soc Biol Fil; 1993; 187(1):37-46. PubMed ID: 8242421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early and late molecular events occurring following neuronal degeneration in the dopamine system.
    Joh TH; Weiser M
    Adv Neurol; 1993; 60():316-20. PubMed ID: 8093580
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogenesis and animal studies of Parkinson's disease.
    Oertel WH; Kupsch A
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):323-32. PubMed ID: 8507901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mitochondrial complex I deficiency in Parkinson's disease.
    Schapira AH
    Adv Neurol; 1993; 60():288-91. PubMed ID: 8420145
    [No Abstract]   [Full Text] [Related]  

  • 6. Is dopaminergic cell death accompanied by concomitant nerve plasticity?
    Anglade P; Blanchard V; Raisman-Vozari R; Faucheux BA; Herrero MT; Obeso JA; Mouatt-Prigent A; Kastner A; Strada O; Javoy-Agid F; Agid Y; Hirsch EC
    Adv Neurol; 1996; 69():195-208. PubMed ID: 8615129
    [No Abstract]   [Full Text] [Related]  

  • 7. Functional consequences of dopaminergic degeneration in Parkinson's disease.
    Tedroff JM
    Adv Neurol; 1999; 80():67-70. PubMed ID: 10410704
    [No Abstract]   [Full Text] [Related]  

  • 8. Mitochondrial energy crisis in Parkinson's disease.
    Mizuno Y; Ikebe S; Hattori N; Kondo T; Tanaka M; Ozawa T
    Adv Neurol; 1993; 60():282-7. PubMed ID: 8420144
    [No Abstract]   [Full Text] [Related]  

  • 9. Glial cell participation in the degeneration of dopaminergic neurons in Parkinson's disease.
    Hirsch EC; Hunot S; Damier P; Brugg B; Faucheux BA; Michel PP; Ruberg M; Muriel MP; Mouatt-Prigent A; Agid Y
    Adv Neurol; 1999; 80():9-18. PubMed ID: 10410697
    [No Abstract]   [Full Text] [Related]  

  • 10. A cloned dopamine transporter. Potential insights into Parkinson's disease pathogenesis.
    Uhl GR; Kitayama S
    Adv Neurol; 1993; 60():321-4. PubMed ID: 8380524
    [No Abstract]   [Full Text] [Related]  

  • 11. Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons.
    Porritt MJ; Batchelor PE; Howells DW
    Exp Neurol; 2005 Mar; 192(1):226-34. PubMed ID: 15698637
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathophysiology of Parkinson's disease.
    Bonnet AM; Houeto JL
    Biomed Pharmacother; 1999 Apr; 53(3):117-21. PubMed ID: 10349507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neurotrophic factors and Parkinson's disease.
    Hefti F; Michel PP; Knusel B
    Adv Neurol; 1990; 53():123-7. PubMed ID: 2239452
    [No Abstract]   [Full Text] [Related]  

  • 14. Time sequences of dopaminergic cell death in Parkinson's disease: indications for neuroprotective studies.
    Gerlach M; Riederer PF
    Adv Neurol; 1999; 80():219-25. PubMed ID: 10410725
    [No Abstract]   [Full Text] [Related]  

  • 15. [Aging, disease and nerve cell death].
    Agid Y
    Bull Acad Natl Med; 1995 Jun; 179(6):1193-203; discussion 1203-7. PubMed ID: 8542348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Parkinson's disease and the adaptive capacity of the nigrostriatal dopamine system: possible neurochemical mechanisms.
    Hornykiewicz O
    Adv Neurol; 1993; 60():140-7. PubMed ID: 8420131
    [No Abstract]   [Full Text] [Related]  

  • 17. Parkinson's disease. The L-dopa era.
    Yahr MD
    Adv Neurol; 1993; 60():11-7. PubMed ID: 8420128
    [No Abstract]   [Full Text] [Related]  

  • 18. Heterogeneity of dopamine receptors.
    Jarvie KR; Caron MG
    Adv Neurol; 1993; 60():325-33. PubMed ID: 8380525
    [No Abstract]   [Full Text] [Related]  

  • 19. Iron metabolism and Parkinson's disease.
    Hirsch EC; Faucheux BA
    Mov Disord; 1998; 13 Suppl 1():39-45. PubMed ID: 9613717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The dopaminergic nigrostriatal system and Parkinson's disease: molecular events in development, disease, and cell death, and new therapeutic strategies.
    Hodaie M; Neimat JS; Lozano AM
    Neurosurgery; 2007 Jan; 60(1):17-28; discussion 28-30. PubMed ID: 17228250
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.